GlassScriptPhysician profile
Anna M Misior
NPI 1023460037
$2,316.75
in general payments reported to CMS, 2019-2025
26 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $426 · 2022: $474 · 2023: $558 · 2024: $478 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,416.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $443.95 | 2021-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $383.95 | 2021-2025 | |
| Novo Nordisk INC | $287.98 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $207.99 | 2023-2025 | |
| Bausch Health US, LLC | $128.62 | 2022-2025 | Wellbutrin, Aplenzin |
| Exact Sciences Corporation | $116.96 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $71.50 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.42 | 2022 | |
| Glaxosmithkline, LLC. | $61.55 | 2023-2024 | Shingrix, Arexvy |
| Gilead Sciences, INC. | $57.71 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $56.89 | 2022-2025 | Breztri, Airsupra |
| Idorsia Pharmaceuticals US INC | $50.10 | 2023 | Quviviq |
| Mayne Pharma Commercial LLC | $46.81 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $45.15 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.36 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $37.33 | 2024 | Veozah |
| Axsome Therapeutics, INC. | $37.17 | 2025 | Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.98 | 2022-2024 | Xifaxan, Trulance |
| Abbott Laboratories | $24.92 | 2021 | |
| Amarin Pharma, INC. | $24.09 | 2021 | |
| Ibsa Pharma INC. | $21.16 | 2022 | |
| Sumitomo Pharma America, INC. | $18.80 | 2023 | Gemtesa |
| Agile Therapeutics, INC. | $15.94 | 2021 | |
| Clarus Therapeutics INC. | $15.59 | 2021 | |
| Merck Sharp & Dohme LLC | $13.46 | 2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Phathom Pharmaceuticals, INC. | $13.37 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Misior listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.